Study intervention and background medication
Following CMIV, patients will be randomly assigned to oral dapagliflozin therapy or matched placebo in blocks of ten. Dapagliflozin will be initiated on the first morning after CMIV at a dose of 10 mg once daily until 3 months post-operation. The start date of the observation will be set as the first intervention date. Patients in both groups will undergo 24-h post-operative rhythm monitoring and will be treated with continuous intravenous amiodarone as the standard of care.All patients will be treated with amiodarone post-operatively, and this trial will test dapagliflozin added to the background medication after CMIV. Routine oral amiodarone at 200 mg twice a day will be administered for 3 months when the patients leave the intensive care unit. Low molecular weight heparin combined with warfarin will be used during the early post-operative period and then treated with warfarin alone after the international normalized ratio (INR) reaches the ideal value (INR of 2.0–3.0).